The number of orphan drug designations doubled between 2007 and 2014; and drugs for rare diseases accounted for 41% of new FDA-approved drugs in 2016. Aided by a variety of supportive FDA policies, orphan drugs have had a higher overall success rate than their counterparts from 2006-2015: 25% of orphan drugs advanced successfully from Phase I to FDA approval versus only 9.6% of nonorphan drugs, spurring investment from companies and giving new hope to patients suffering from heretofore untreatable diseases. Read this article to find out more.
Other content in this Stream
The COVID-19 global pandemic has had a significant impact on the conduct of pediatric and adult clinical drug trials. Many trials have halted enrollment, and there are multiple challenges with...
In clinical trials for cellular and gene therapies, the COVID-19 pandemic has created enormous complexities. Parexel experts Matthew M. Cooney, MD and Roberta L. Steere offer a brief overview.
Learn more about key considerations when selecting the right wearable device for your clinical trial.
Read this article by Parexel's Rosamund Round, Head of Parexel's Patient Innovation Center, that appeared in Applied Clinical Trials.
Learn about patient recruitment strategies in Asia that will reduce the clinical trial burden, as published in Pharma Focus Asia in January 2018.
Parexel's newly enhanced Medical Writing Solutions can help you optimize and better manage the development of documents and communications from early clinical development through commercialization.
Find out how Parexel uses feedback from clinical site investigator surveys.